



Tirzepatide 10mg Easy Pen



**HIGH-EFFICACY WEIGHT LOSS,
GLUCOSE BALANCE, HEART
& LIVER PROTECTION**

Easy Pen

Tirzepatide is a dual GIP and GLP-1 receptor agonist that combines two powerful metabolic pathways in one therapy. This "twincrutin" approach supports dramatic weight loss, improved insulin sensitivity, and enhanced fat and liver metabolism.

Clinical trials report over 20% body weight reduction and major improvements in blood sugar and cardiometabolic health. By suppressing appetite, stabilizing glucose, and boosting fat-burning, Tirzepatide offers a potent, multi-system reset for comprehensive metabolic support.

Key Potential Benefits

- **Exceptional Weight Loss** – In SURMOUNT-1, up to 20.9% body weight reduction at 72 weeks (15 mg dose); most users lose ≥20%.
- **Superior Glycemic Control** – Dose-dependent HbA1c drops in diabetes, outperforming GLP-1-only agents.
- **Visceral & Liver Fat Reduction** – Significant reductions in abdominal adiposity and liver fat, improving NAFLD/MASLD biomarkers.
- **Cardiovascular & Heart Failure Support** – 38% lower risk of hospitalization/death in HFpEF; favorable impact on MACE and lipid markers.
- **Kidney & All-Cause Mortality Benefits** – Observational studies show reduced risk of major cardiovascular events, kidney outcomes, and death.
- **Improved Lipid Panel** – Dropped total cholesterol, LDL, and triglycerides while raising HDL.
- **Lean Mass Preservation** – Rapid fat loss without sacrificing muscle mass or metabolic rate.
- **Appetite Suppression & Satiety Support** – Dual-hormone action increases fullness while reducing cravings and lowering calorie intake.

Technical Information:

CAS Number: 2023788-19-2

PubChem CID: [163285896](#)

Formula: C227H352N48O70

Specifications:

- 0.05mg per click.
- Up to 60 clicks per dose.
- Includes 4 needles and one adjustable dosage pre-mixed pen.



[View Online](#)